Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
Titel:
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
Auteur:
Yamazaki, K. Nagase, M. Tamagawa, H. Ueda, S. Tamura, T. Murata, K. Eguchi Nakajima, T. Baba, E. Tsuda, M. Moriwaki, T. Esaki, T. Tsuji, Y. Muro, K. Taira, K. Denda, T. Funai, S. Shinozaki, K. Yamashita, H. Sugimoto, N. Okuno, T. Nishina, T. Umeki, M. Kurimoto, T. Takayama, T. Tsuji, A. Yoshida, M. Hosokawa, A. Shibata, Y. Suyama, K. Okabe, M. Suzuki, K. Seki, N. Kawakami, K. Sato, M. Fujikawa, K. Hirashima, T. Shimura, T. Taku, K. Otsuji, T. Tamura, F. Shinozaki, E. Nakashima, K. Hara, H. Tsushima, T. Ando, M. Morita, S. Boku, N. Hyodo, I.